MARK COOPER, MD
Osteopathic Medicine at Metrohealth Dr, Cleveland, OH
License number
Ohio 35059416
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
2500 Metrohealth Dr, Cleveland, OH 44109
Phone
(216) 778-5790
Personal information
See more information about MARK COOPER at radaris.comName
Address
Phone
496 Brittain Rd #3, Akron, OH 44305
4507 State Route 743, Moscow, OH 45153
509 Corwin St, Defiance, OH 43512
548 Oak Knoll Ave SE, Warren, OH 44483
5715 Arlyne Ln, Medina, OH 44256
Professional information
Operations Manager At Dematic
Position:
Operations Manager at Dematic
Location:
Cleveland/Akron, Ohio Area
Industry:
Logistics and Supply Chain
Work:
Dematic
-
Operations Manager
Mark Cooper - Bedford Hts, OH
Work:
Spectrum Technologies
Document Imaging Technician Regency Technologies
Desktop Breakdown Technician
Document Imaging Technician Regency Technologies
Desktop Breakdown Technician
Education:
Cleveland Institute of Electronics - Cleveland, OH
A+ Certification
A+ Certification
Dr. Mark J Cooper, Cleveland OH - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
11000 Cedar Ave SUITE 145, Cleveland 44106
(216) 231-0227 (Phone)
(216) 231-0227 (Phone)
Certifications:
Internal Medicine, 1985, Medical Oncology, 1987
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
11000 Cedar Ave SUITE 145, Cleveland 44106
University Hospitals Case Medical Center
11100 Euclid Ave, Cleveland 44106
University Hospitals Case Medical Center
11100 Euclid Ave, Cleveland 44106
Education:
Medical School
Johns Hopkins University School Of Medicine
Graduated: 1982
Johns Hopkins Hospital
Graduated: 1983
Johns Hopkins
Graduated: 1985
National Canc Institute
Graduated: 1988
Johns Hopkins University School Of Medicine
Graduated: 1982
Johns Hopkins Hospital
Graduated: 1983
Johns Hopkins
Graduated: 1985
National Canc Institute
Graduated: 1988
Dr. Mark J Cooper, Cleveland OH - MD (Doctor of Medicine)
Specialties:
Hematology, Hematology & Oncology
Address:
METROHEALTH MEDICAL CENTER
2500 Metrohealth Dr SUITE C-2001, Cleveland 44109
(216) 778-8305 (Phone), (216) 778-3328 (Fax)
2500 Metrohealth Dr, Cleveland 44109
(216) 778-5360 (Phone), (216) 778-5360 (Fax)
2500 Metrohealth Dr SUITE C-2001, Cleveland 44109
(216) 778-8305 (Phone), (216) 778-3328 (Fax)
2500 Metrohealth Dr, Cleveland 44109
(216) 778-5360 (Phone), (216) 778-5360 (Fax)
Languages:
English
Education:
Medical School
Johns Hopkins University / School of Medicine
Johns Hopkins University / School of Medicine
Episomal Expression Vector For Human Gene Therapy
US Patent:
6339065, Jan 15, 2002
Filed:
Jan 30, 1996
Appl. No.:
08/594299
Inventors:
Mark J. Cooper - Solon OH
Assignee:
Case Western Reserve University - Cleveland OH
International Classification:
A61K 3170
US Classification:
514 44, 435 691, 435455
Abstract:
Episomal plasmids containing a papovavirus origin of replication and a papovavirus large T antigen mutant form are shown to replicate episomally in human cells, and yield levels of gene expression proportional to their episomal copy number. In conjunction with liposomal or receptor-mediated delivery systems, papovavirus-derived episomal plasmids provide an alternative vector for gene therapy, particularly when utilizing strategies requiring high levels of gene expression.
Method Of Nucleic Acid Compaction
US Patent:
6506890, Jan 14, 2003
Filed:
Nov 28, 2000
Appl. No.:
09/722340
Inventors:
Mark J. Cooper - Solon OH 44139
Tomasz H. Kowalczyk - University Heights OH 44118
Murali Krishna Pasumarthy - Willoughby Hills OH 44092
Tomasz H. Kowalczyk - University Heights OH 44118
Murali Krishna Pasumarthy - Willoughby Hills OH 44092
International Classification:
C07H 2102
US Classification:
536 231, 536 221, 435 6, 435 71, 435 911, 435 912
Abstract:
An automated nucleic acid compaction device for analyzing and compacting a nucleic acid complex into unimolecular nucleic acid particles. Broadly, the device includes a container support and agitation system; a measuring and testing system; and a dispensing system; all controlled by a control system. The control system controls the support and agitation system and the dispensing system based either on a predetermined formulation or by analysis of feedback data provided by the measuring and testing system. In a preferred embodiment, the device is a real-time measuring and mixing instrument operating in a closed loop system. The preferred embodiment also comprises a monitoring system including a submersible probe which is positioned in the batch solution to provide data to a controller. Once a desired level of nucleic acid compaction is reached, as detected by the monitoring system, the controller stops the dispensing and mixing agitating systems.
Mark Cooper, Cleveland OH
Specialties:
Internist
Address:
2500 Metrohealth Dr, Cleveland, OH 44109
Automated Nucleic Acid Compaction Device
US Patent:
6281005, Aug 28, 2001
Filed:
May 14, 1999
Appl. No.:
9/311553
Inventors:
Hector L. Casal - Shaker Heights OH
Mark J. Cooper - Solon OH
Tomasz H. Kowalczyk - University Heights OH
Murali Krishna Pasumarthy - Willoughby Hills OH
Jose C. Perales - Barcelona, ES
Steven J. Torontali - Moreland Hills OH
Mark J. Cooper - Solon OH
Tomasz H. Kowalczyk - University Heights OH
Murali Krishna Pasumarthy - Willoughby Hills OH
Jose C. Perales - Barcelona, ES
Steven J. Torontali - Moreland Hills OH
Assignee:
Copernicus Therapeutics, Inc. - Cleveland OH
International Classification:
C12M 134, C12Q 168, C07H 1900, A61K 4800, G01N 1502
US Classification:
4352872
Abstract:
An automated nucleic acid compaction device for analyzing and compacting a nucleic acid complex into unimolecular nucleic acid particles. Broadly, the device includes a container support and agitation system; a measuring and testing system; and a dispensing system; all controlled by a control system. The control system controls the support and agitation system and the dispensing system based either on a predetermined formulation or by analysis of feedback data provided by the measuring and testing system. In a preferred embodiment, the device is a real-time measuring and mixing instrument operating in a closed loop system. The preferred embodiment also comprises a monitoring system including a submersible probe which is positioned in the batch solution to provide data to a controller. Once a desired level of nucleic acid compaction is reached, as detected by the monitoring system, the controller stops the dispensing and mixing agitating systems.
Episomal Expression Vector For Human Gene Therapy
US Patent:
5624820, Apr 29, 1997
Filed:
Jun 7, 1995
Appl. No.:
8/479204
Inventors:
Mark J. Cooper - Solon OH
Assignee:
Case Western Reserve University - Cleveland OH
International Classification:
C12P 2106, C12N 1537, C12N 1585
US Classification:
435 691
Abstract:
Episomal plasmids containing a papovavirus origin of replication and a papovavirus large T antigen mutant form are shown to replicate episomally in human cells, and yield levels of gene expression proportional to their episomal copy number. In conjunction with liposomal or receptor-mediated delivery systems, papovavirus-derived episomal plasmids provide an alternative vector for gene therapy, particularly when utilizing strategies requiring high levels of gene expression.
Methods For Identifying Oncogenes And Anti-Oncogenes
US Patent:
5770374, Jun 23, 1998
Filed:
Oct 10, 1996
Appl. No.:
8/728608
Inventors:
Mark J. Cooper - Solon OH
Assignee:
Case Western Reserve University - Cleveland OH
International Classification:
C12Q 168
US Classification:
435 6
Abstract:
Episomal plasmids containing a papovavirus origin of replication and a papovavirus large T antigen mutant form are shown to replicate episomally in human cells, and yield levels of gene expression proportional to their episomal copy number. Candidate oncogenes and anti-oncogenes can be identified by transfecting the episomal plasmids containing a candidate oncogene or anti-oncogene into non-tumorigenic cells and screening for a tumorigenic phenotype.